Equillium, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $4.7 million, a decrease from a net loss of $5.7 million in the same period of 2025. For the first half of 2026, the company recorded a net loss of $10.0 million, down from $14.4 million in the prior year. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $2.7 million for the quarter, compared to $4.1 million in the second quarter of 2025. The total operating expenses for the second quarter were $5.2 million, down from $6.2 million year-over-year.
Equillium's cash and cash equivalents increased to $57.2 million as of June 30, 2026, compared to $30.3 million at the end of 2025. This increase was primarily driven by a successful equity financing in March 2026, which generated approximately $35.0 million in gross proceeds. The company’s accumulated deficit now stands at $226.2 million, reflecting its ongoing investment in research and development without generating product sales to date.
In terms of operational developments, Equillium is advancing its lead product candidate, EQ504, a novel aryl hydrocarbon receptor modulator, into clinical development. The company plans to initiate a Phase 1 placebo-controlled study for EQ504 in the fourth quarter of 2026, with data expected approximately six months thereafter. Additionally, Equillium has initiated IND-enabling development activities for EQ504 as a potential inhaled therapy for inflammatory lung diseases. The company also holds exclusive worldwide rights to EQ302, a preclinical-stage product candidate targeting gastrointestinal diseases.
Equillium's workforce has seen changes, with a reduction in headcount contributing to lower general and administrative expenses, which totaled $2.4 million for the second quarter of 2026, compared to $2.1 million in the same period last year. The company anticipates that its existing cash reserves will be sufficient to fund operations into 2029, although it expects to continue incurring significant losses as it advances its research and development activities. Looking ahead, Equillium plans to finance its operations through a combination of equity offerings, debt financings, and potential collaboration agreements, while acknowledging the uncertainties and challenges posed by current market conditions.
About Equillium, Inc.
Equillium, Inc. is a biotechnology company focused on developing novel immuno-inflammatory therapeutics. Its pipeline includes first-in-class monoclonal antibodies and multi-cytokine inhibitors targeting severe autoimmune and inflammatory diseases such as graft-versus-host disease, celiac disease, and alopecia areata. The company leverages proprietary platforms and strategic partnerships to advance clinical candidates and aims to commercialize therapies that address high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov